# A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis

> **NCT05265923** · PHASE3 · COMPLETED · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 500 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** CM310
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05265923
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-22
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-12-25
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265923, "A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05265923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*